Moshe Rubin, MD
Gastroenterology · New York, NYNPI 1134217078
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 78 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 14 manufacturers, the largest accounting for just 19.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,506 and has fallen 93.8% since, to $94 in 2025. That places this record below the midpoint for gastroenterology clinicians in NY, where the typical reported total is $1,827.
Across 78 payments — averaging $26.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$413
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$344
- Fujifilm Healthcare Americas Corporation$297
- QOL Medical, LLC$200
- Takeda Pharmaceuticals U.S.A., Inc.$155
- Olympus America Inc.$149
- plus $514 from 8 others
Across 2 payments — averaging $3000.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bausch Health US, LLC$6K
What the payments were for
- Food & beverage$2,071100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 11 | $413 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 19 | $344 |
| Fujifilm Healthcare Americas Corporation | 2 | $297 |
| QOL Medical, LLC | 18 | $200 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $155 |
| Olympus America Inc. | 1 | $149 |
| Boston Scientific | 1 | $145 |
| Intercept Pharmaceuticals, Inc. | 1 | $123 |
| Ferring Pharmaceuticals Inc. | 6 | $110 |
| Johnson & Johnson | 2 | $46 |
| Pfizer | 1 | $30 |
| Exact Sciences | 1 | $21 |
| Ironwood Pharmaceuticals, Inc | 1 | $20 |
| Shire North American Group Inc | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ESD - Core Endoscopy$297
- EVIS EXERA$149
- GENERAL ENDOCHOICE$145
- Humira$139
- OCALIVA$123
- Mavyret$121
How this compares
$2,071 in reported general payments places this provider in the 50th percentile of 1,682 gastroenterology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MotegrityPrucalopride Succinate | 17 | $12,421 |
| Mesalamine | 12 | $5,274 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 20 | $3,400 |
| Rabeprazole Sodium | 39 | $1,820 |
| Colestipol Hcl | 16 | $880 |
| CholestyramineCholestyramine (With Sugar) | 11 | $810 |
| Famotidine | 12 | $177 |
| Omeprazole | 12 | $36 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $155 | $12,42117 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $110 | $3,40020 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,682 gastroenterology providers in New York.
Other gastroenterology in New York
- David Carr LockeNew York$2M
- Arthur KornbluthNew York$1.9M
- Sonal KumarNew York$1M
- David PoppersNew York$939K
- Ellen ScherlNew York$857K
- Bruce SandsNew York$810K
- Jean Frederick ColombelNew York$786K
- Seth GrossNew York$624K
- Caterina Oneto ArayaNew York$610K
- Dana LukinNew York$491K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.